1
|
Seldeen KL, Halley PG, Volmar CH, Rodríguez MA, Hernandez M, Pang M, Carlsson SK, Suva LJ, Wahlestedt C, Troen BR, Brothers SP. Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater bone mineral density. Neuropeptides 2018; 67:45-55. [PMID: 29129406 PMCID: PMC5805636 DOI: 10.1016/j.npep.2017.11.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2017] [Revised: 11/06/2017] [Accepted: 11/06/2017] [Indexed: 12/15/2022]
Abstract
Osteoporosis, a disease characterized by progressive bone loss and increased risk of fracture, often results from menopausal loss of estrogen in women. Neuropeptide Y has been shown to negatively regulate bone formation, with amygdala specific deletion of the Y2 receptor resulting in increased bone mass in mice. In this study, ovariectomized (OVX) mice were injected once daily with JNJ-31020028, a brain penetrant Y2 receptor small molecule antagonist to determine the effects on bone formation. Antagonist treated mice had reduced weight and showed increased whole-body bone mineral density compared to vehicle-injected mice. Micro computerized tomography (micro-CT) demonstrated increased vertebral trabecular bone volume, connectivity density and trabecular thickness. Femoral micro-CT analysis revealed increased bone volume within trabecular regions and greater trabecular number, without significant difference in other parameters or within cortical regions. A decrease was seen in serum P1NP, a measure used to confirm positive treatment outcomes in bisphosphonate treated patients. C-terminal telopeptide 1 (CTX-1), a blood biomarker of bone resorption, was decreased in treated animals. The higher bone mineral density observed following Y2 antagonist treatment, as determined by whole-body DEXA scanning, is indicative of either enhanced mineralization or reduced bone loss. Additionally, our findings that ex vivo treatment of bone marrow cells with the Y2 antagonist did not affect osteoblast and osteoclast formation suggests the inhibitor is not affecting these cells directly, and suggests a central role for compound action in this system. Our results support the involvement of Y2R signalling in bone metabolism and give credence to the hypothesis that selective pharmacological manipulation of Y2R may provide anabolic benefits for treating osteoporosis.
Collapse
Affiliation(s)
- K L Seldeen
- Division of Geriatrics and Palliative Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; Research Service, Veterans Affairs Western New York Healthcare System, Buffalo, NY, USA
| | - P G Halley
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
| | - C H Volmar
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
| | - M A Rodríguez
- Bruce W. Carter VA Geriatric Research Education and Clinical Center (GRECC), Miami, FL, USA; University of Miami Miller School of Medicine, Miami, FL, USA
| | - M Hernandez
- Bruce W. Carter VA Geriatric Research Education and Clinical Center (GRECC), Miami, FL, USA; University of Miami Miller School of Medicine, Miami, FL, USA
| | - M Pang
- Division of Geriatrics and Palliative Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; Research Service, Veterans Affairs Western New York Healthcare System, Buffalo, NY, USA
| | - S K Carlsson
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
| | - L J Suva
- Department of Orthopaedic Surgery, Centre for Orthopaedic Research, University of Arkansas Medical School, Little Rock, AR, USA
| | - C Wahlestedt
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
| | - B R Troen
- Division of Geriatrics and Palliative Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; Research Service, Veterans Affairs Western New York Healthcare System, Buffalo, NY, USA
| | - S P Brothers
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
| |
Collapse
|
2
|
Sartor GC, Powell SK, Wiedner HJ, Wahlestedt C, Brothers SP. Nociceptin receptor activation does not alter acquisition, expression, extinction and reinstatement of conditioned cocaine preference in mice. Brain Res 2015; 1632:34-41. [PMID: 26657743 DOI: 10.1016/j.brainres.2015.11.044] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2015] [Revised: 11/24/2015] [Accepted: 11/27/2015] [Indexed: 10/22/2022]
Abstract
Growing evidence indicates that targeting nociceptin receptor (NOP) signaling may have therapeutic efficacy in treating alcohol and opioid addiction. However, little is known about the therapeutic value of selective NOP agonists for the treatment of cocaine dependence. Recently, we identified a highly selective, brain-penetrant NOP small molecule agonist (SR-8993), and using this compound, we previously showed that nociceptin receptor activation attenuated consolidation of fear-related memories. Here, we sought to determine whether SR-8993 also affects the rewarding properties of cocaine. Using a conditioned place preference (CPP) procedure, we show that SR-8993 (3 or 10 mg/kg) failed to disrupt acquisition or expression of cocaine CPP (7.5 or 15 mg/kg) in C57BL/6 mice. Additionally, SR-8993 did not affect rate of extinction or reinstatement (yohimbine- and cocaine-induced) of cocaine CPP. These studies indicate that selective activation of NOP may not be sufficient in reducing behavioral responses to cocaine.
Collapse
Affiliation(s)
- G C Sartor
- Center for Therapeutic Innovation (CTI) and Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine
| | - S K Powell
- Center for Therapeutic Innovation (CTI) and Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine
| | - H J Wiedner
- Center for Therapeutic Innovation (CTI) and Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine
| | - C Wahlestedt
- Center for Therapeutic Innovation (CTI) and Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine
| | - S P Brothers
- Center for Therapeutic Innovation (CTI) and Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine
| |
Collapse
|